WO2024023659 - PHARMACEUTICAL COMPOSITIONS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR AND METHODS FOR MAKING SAME
National phase entry:
Publication Number
WO/2024/023659
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057404
International Filing Date
20.07.2023
Title **
[English]
PHARMACEUTICAL COMPOSITIONS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR AND METHODS FOR MAKING SAME
[French]
COMPOSITIONS PHARMACEUTIQUES D'INHIBITEUR DE KARS DÉPENDANT D'AKR1C3 TRICYCLIQUE ET LEURS PROCÉDÉS DE FABRICATION
Applicants **
NOVARTIS AG
Inventors
GRANER, Oliver
HARLACHER, Cornelius
Priority Data
63/369,407
26.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2945 | |
| EPO | Filing, Examination, Granting | 22351 | |
| Japan | Filing, Examination, Granting | 2986 | |
| South Korea | Filing, Examination, Granting | 3757 | |
| USA | Filing, Examination, Granting | 16340 |
Total:
48,379
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to solid phase pharmaceutical compositions of 6'-fluoro-N-(4-fluorobenzyl)-4'-oxo-3',4'-dihydro-1'H-spiro[piperidine-4,2'-quinoline]-1-carboxamide that is useful as a AKR1C3 dependent KARS inhibitor. The present invention also relates to processes for the preparation of said pharmaceutical compositions of said compound, methods of using said pharmaceutical compositions in the treatment of various diseases and disorders, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.[French]
La présente invention concerne des compositions pharmaceutiques en phase solide de 6'-fluoro-N-(4-fluorobenzyl)-4'-oxo-3',4'-dihydro-1'H-spiro[pipéridine-4,2'-quinoline]-1-carboxamide qui est utile en tant qu'inhibiteur de KARS dépendant d'AKR1C3. La présente invention concerne également des procédés de préparation desdites compositions pharmaceutiques dudit composé, des procédés d'utilisation desdites compositions pharmaceutiques dans le traitement de troubles et maladies divers, et leur utilisation dans des maladies et des troubles à médiation par un inhibiteur de KARS dépendant d'AKR1C3.